Spruce Biosciences, Inc. (SPRB)

Market Cap	5.45M
Revenue (ttm)	4.91M
Net Income (ttm)	-53.04M
Shares Out	41.30M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,509,156
Open	0.1847
Previous Close	0.3144
Day's Range	0.1255 - 0.1894
52-Week Range	0.1255 - 0.8700
Beta	2.39
Analysts	Hold
Price Target	2.25 (+1,604.55%)
Earnings Date	Apr 15, 2025

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB
• Website: https://sprucebio.com

Financial Performance

In 2024, Spruce Biosciences's revenue was $4.91 million, a decrease of -51.32% compared to the previous year's $10.09 million. Losses were -$53.04 million, 10.7% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $2.25, which is an increase of 1,604.55% from the latest price.

Price Target

$2.25

(1,604.55% upside)

Analyst Consensus: Hold